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1040-71 Interhospital Transfers Are Costly, Cause Delays and Do 
Not Address the Imbalance of Access to 
Revascularization: The Case for More Angiographic 
Facilities? Results From the Global Registry of Acute 
Coronary Events
Ameet Bakhai, Omar H. Dabbous, David J. Cohen, Marcus D. Flather, Dan Greenberg, 
Frederick A. Anderson, Jr., Enrique P. Gurfinkel, Kami White, Keith A.A Fox, The GRACE 
Investigators, Royal Brompton Hospital, London, United Kingdom
Background Hospital revascularization rates for patients (pts) admitted with acute coro-
nary syndromes (ACS) vary depending on proximity to a hospital capable of coronary
revascularization. We examined whether interhospital transfers balance out these varia-
tions and represent the most effective use of resources.
Methods We compared clinical outcomes, resource use and costs for ACS pts enrolled
in GRACE to Dec ’02, presenting directly to centers with (Rv+) or without (Rv-) 24h
access to revasc (PCI/CABG) facilities and for pts transferred (Tr) to a Rv+ unit for acute
care. Costs were estimated ($/€) using key drivers: length of stay, ward type and use of
PCI, stent or CABG.
Results 25,344 pts presented initially to Rv+ (74%) and Rv- (26%). Almost 1 in 5 pts
needed acute Tr. Overall hospital mortality rates were similar (5.4%) for Rv+ and Rv- pts.
Mean cost of all ACS pts was $6001/€5253. Almost 1 in 3 Tr pts did not proceed to
revasc. In the UK alone, the estimated cost of care of Tr pts annually would be $50(€42)
million.
Conclusions Tr rates would have to increase from 20% to 60% to balance the substan-
tial differences in revasc rates between centers. Access to angiography before Tr would
realise substantial potential cost savings by avoiding Tr for pts unlikely to proceed to
revasc. Further economic data is urgently needed to determine the most optimal use of
resources. Increased angiographic facilities may also allow more equitable access to
early revasc for all ACS pts with suitable anatomy.
1040-72 Are American College of Cardiology/American Heart 
Association Preoperative Practice Guidelines for Stress 
Testing Followed?
Howard Weinstein, Barbara Spaltro, Richard M. Steingart, Memorial Sloan-Kettering 
Cancer Center, New York, NY
Background: ACC/AHA preoperative practice guidelines for stress testing are widely
promulgated but the extent to which they are followed and applicable in specialized popu-
lations is unknown.
Methods: Accordingly, we retrospectively applied the ACC/AHA preoperative guidelines
to a group of 776 consecutive patients (pts) undergoing abdominal, genitourinary, head
and neck or thoracic cancer surgery referred for preoperative exercise stress echocardio-
graphy (ESE).
Results: Eighty-four percent of stress tests were not indicated by existing ACC/AHA
guidelines. The rate of cardiac events (AMI, CHF, UA and death ) in these pts was low
(1.8%) and ESE provided no further risk stratification (Fig). In pts where stress testing
was indicated by the guidelines, the event rate was 7%. ESE provided further risk stratifi-
cation in this group (Fig).
Conclusions: 1) Compliance with preoperative stress testing guidelines in this popula-
tion is poor, resulting in extensive testing that provides no further risk stratification. 2)
Where stress testing is indicated by guidelines, ESE provides important prognostic infor-
mation.
1040-73 Financial Impact of Drug-Eluting Stents: The US 
Academic Experience
David S. Marks, Thomas A. Ratko, Karl A. Matuszewski, Michael J. Oinonen, Joseph P. 
Cummings, Medical College of Wisconsin, Milwaukee, WI, University HealthSystem 
Consortium, Oak Brook, IL
Background: Drug-eluting stents (DES) have recently been released in the United States
in limited quantity. These stents have changed the financial impact of coronary interven-
tion. The impact of DES in the initial US rollout has not been described.
Methods: The University HealthSystem Consortium (UHC) is an alliance of 87 academic
health centers in the US. The UHC clinical database was queried for DES implantation
compared to bare stent implantation for the second quarter (Q2) of 2003. This database
contains a comprehensive collection of procedure-specific data derived from discharge
abstract summaries and UB-92 data for all inpatients at participating centers.
Results: 11,866 procedures involving coronary stents from 74 institutions performed in
Q2 were analyzed, including 3,404 procedures using DES. Penetration of DES increased
monthly and reached 44% by June, 2003. Mean length of stay was lower for DES proce-
dures compared to bare stent procedures both with myocardial infarction (MI) (3.51±2.84
vs. 3.98±3.47 days, p<0.01) and without MI (1.99±2.29 vs.2.39±2.98, p<0.01). Overall
procedural costs increased for DES both with myocardial infarction ($18,150±9,900 vs.
$17,225±10,500) and without ($13,400±8,200 vs. $14,953±8,200). No difference existed
in payer status or clinical demographics between bare stents and DES.
Conclusion: The introduction of DES has increased costs to health care centers and the
technology has had rapid adoption despite limited supply. Yet, retrospective database
analysis suggests the cost of caring for patients with DES has risen by a quantity less
than the incremental price of a single stent; this may be explained, in part, by a
decreased LOS. No patient clinical or demographic criteria attesting to this savings has
been ascertained by a comprehensive clinical database. Further investigation is required
to understand the patient and physician characteristics that have determined DES utiliza-
tion and non-stent cost savings.
1040-74 Drug-Eluting Stent Use May Negatively Impact the 
Economic Health of a Hospital: A Single-Center Case 
Study
Richard E. Sinaiko, Mikele M. Bunce, Neal Eigler, Saibal Kar, Sepideh S. Farivar, Emma 
C. Wollschlager, Sinaiko Healthcare Consulting, Inc., Los Angeles, CA, Cedars-Sinai 
Health System, Los Angeles, CA
Background: Drug eluting stents (DES) are becoming the "gold standard" for treatment
of coronary artery disease due to decreased rates of restenosis. The economic implica-
tions of this costly technology may be greater than expected. This study was conducted
to forecast the financial impact of DES use on a major teaching hospital.
Methods: A case study hospital’s caseload, cost, and reimbursement data were used to
perform a sensitivity analysis using a financial impact model developed by Cordis, which
was run using two different sets of assumptions: (1) Cordis’ assumptions, and (2) case
study hospital’s assumptions. The case study hospital's assumptions were obtained by
surveying a group of the hospital’s interventional cardiologists.
Results: The results of this study (Figure 1) show that while Cordis’ assumptions show
less of an impact, under both Cordis’ and the case study’s assumptions, the case study
hospital will undergo a significant reduction in cardiovascular service line contribution
margin as a result of drug eluting stent use.
Conclusions: Hospitals have little control over the financial impact of DES due to
demand, liability, and guideline enforcement issues. To relieve the burden hospitals face
and to ensure the healthcare community has appropriate incentives to practice in a cost-
effective and patient centered way, Medicare should increase its reimbursement rates for
IMGs CMGs Adjusted Odds 
Ratio IMGs/CMGs 
(95% CI)
Medications within 90 days of hospital 
discharge, (%)
Aspirin 61.4 60.4 1.00 (0.94, 1.06)
Beta Blockers 53.8 56.4 1.01 (0.94, 1.07)
ACE inhibitors 51.3 52.0 1.04 (0.98, 1.11)
Statins 19.1 19.8 1.09 (1.01, 1.19)
Cardiac Procedures within 1 year of hospital 
discharge, (%)
Cardiac Catheterizations 31.0 32.6 1.06 (1.01, 1.18)
PCI 9.1 9.9 1.06 (1.00, 1.13)
CABG 9.6 10.3 1.00 (0.95, 1.06)
Category Admitted to 
Rev+ (n=18,817)
Admitted to 
Rev- (n=6527)
Transferred to 
Rev+ (n=3093)
USA pts in category (%) 22.1 20.4 41.3
Mean age (years) 65.5 66.7 62.6
+ve cardiac markers (init/pk; 
%)
63.0 57.7 76.5
Pts receiving PCI/CABG (%) 35.3/6.2 *2.6/0.5 50.5/10.9
Discharge-transfer to acute 
facility (%)
4.3 19.5 6.0
Total length of stay, days, 
mean (med) [95%CI]
8.9 (7.0) [8.8, 9.0] 8.5 (7.0) [8.3, 
8.7]
9.8 (7.0) [9.5, 
10.0]
Total index hospital costs, 
mean (med)[95%CI]
Europe
5595 
(4671)[5557, 
5633]
4267 
(3752)[4224, 
4310]
6732 (5428)[6628, 
6836]
US 6712 (5171) 
[6665, 6759]
3953 (3299) 
[3910, 3996]
8572 (7878) 
[8450, 8694]
Note all comparisons (1 vs 2) & (1 vs 3) P<0.001 except Wilcoxon for length of stay
*Some Rev- centers were linked to Rev+ centers as one combined trust
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procedures that use DES.
Figure 1: Predicted contribution margin reduction at a case study hospital (in 000s)
1040-75 Population Rates of Invasive Cardiac Procedures in 
British Columbia, 1995-2001
Gordon E. Pate, Karin H. Humphries, Mona Izadnegahdar, Min Gao, Michael Kiely, 
Ronald G. Carere, Saint Paul's Hospital, Vancouver, BC, Canada, Centre for Health 
Evaluation and Outcomes Sciences, Vancouver, BC, Canada
Background: This audit examined the age-sex standardized population rates of coronary
angiography (CA), percutaneous intervention (PCI) and coronary artery bypass surgery
(CABG) in British Columbia (BC) between 1995 and 2001.
Methods: Data sources were as follows: CABG-BC Cardiac Registry, CA and PCI- BC
Medical Services Plan, Acute Coronary Syndromes (ACS, ICD9 codes 410,411,413)-
Hospital Separation database,population data-BC Statistics. All rates are age and sex
standardized per 100,000 BC resident adults over 20 years.
Results: The rates of diagnostic CA and PCI have increased from 352 and 101 per
100,000 in 1995 to 400 and 154 per 100,000 respectively in 2001 (p<0.01). Single stage
‘ad hoc’ PCI increased from 38% in 1995 to 68% in 2001. The stenting rate increased
dramatically from 25% of PCI procedures in 1995 to 90% in 2001 (p<0.01). The rate of
CABG remained stable at between 70-79 per 100,000. There was a downward trend in
the annual hospitalized incidence of ACS (477 to 430, p=0.04). The incidence of ACS
and the rates of CA, PCI and CABG were higher for men in all age groups. PCI was more
common than CABG in all groups.
Conclusion: The incidence of ACS in British Columbia is falling. The rates of SCA and
PCI are increasing. This may reflect an appropriate evidence-based response to data
supporting greater application of coronary angiography following acute coronary syn-
dromes after publication of several studies supporting a routine invasive approach.
Table:
1040-76 30-Day Mortality Trends Following Acute Myocardial 
Infarction in the Elderly
Judith H. Lichtman, Yun Wang, Sharon-Lise Normand, Rhuna Shen, Lawrence M. Brass, 
Harlan M. Krumholz, Yale University School of Medicine, New Haven, CT
Background. Despite numerous innovations in prevention, diagnosis and treatment of
acute myocardial infarction (AMI), relatively little is known about how these changes have
modified short-term mortality outcomes over time, especially for elderly patients. Current
estimates have generally been derived from small geographic areas, or voluntary regis-
tries that may not be generalizable beyond participating locations or institutions. We
sought to examine national 30- day mortality trends following an AMI among elderly
Medicare beneficiaries (benes).
Methods. All fee-for-service (FFS) Medicare benes 65 years of age or older, discharged
with an AMI (ICD-9 410.xx) from 1993-1999 were included in the study. AMI patients dis-
charged from non-acute facilities, transfers, repeat admissions within 8 weeks, or those
with less than 12 months of continuous FFS status were excluded. Risk adjustment vari-
ables included demographics, and comorbidities and cardiac procedures identified from
hospitalizations within the prior year. Observed and expected 30-day mortality rates were
calculated for age (65-74, 75-84, 85+) and gender subgroups. Logistic regression models
compared annual mortality rates relative to 1993, with adjustment for demographic and
clinical factors.
Results. There were a total of 1,814,196 AMI discharges from 1993-1999. Annual unad-
justed mortality rates remained stable over time (range of 19-20%), despite trends of
increasing comorbidities, cardiac procedures, and advancing mean age of the AMI benes
over the time period. Women had a modest decline in mortality within all age groups, but
rates for men remained relatively stable, with a slight increase for men 85+ years of age.
Risk adjusted annual mortality rates remained essentially unchanged over time (OR
1.01, 95% CI 1.00-1.03; 1.03, 1.01-1.04; 1.01, 0.99-1.02; 0.99, 0.97-1.00; 0.98, 0.97-
1.00; and 1.01; 1.00-1.03).
Conclusions. Despite minor decreases in mortality for women within all age groups, the
absolute decreases in mortality rates are negligible. It is unclear whether the static rates
signal limitations of current therapeutic options, the increasing complexity of AMI
patients, or a combination of these factors.
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1058 Medical Simulation: Tools for Learning on 
the Horizon
Sunday, March 07, 2004, 3:00 p.m.-5:00 p.m.
Morial Convention Center, Hall G
Presentation Hour: 4:00 p.m.-5:00 p.m.
1058-67 Durability of Bioprosthetic Aortic Valves: What Is the 
Re-Operation Risk for My Patients?
John Puvimanasinghe, Johanna Takkenberg, Marinus Eijkemans, Ewout Steyerberg, Lex 
van Herwerden, Eric Jamieson, Gary Grunkemeier, Dik Habbema, Ad Bogers, Erasmus 
Medical Center, Rotterdam, The Netherlands, Providence Health System, Portland, OR
Background: A drawback to the choice of bioprostheses for aortic valve replacement
(AVR) is their limited durability and resultant need for re-operation. The purpose of this
study was to quantify and compare structural valvular deterioration (SVD), re-operation-
free life expectancy and the lifetime risk of re-operation after aortic valve replacement
with three widely used bioprostheses respectively.
Methods: We used long-term follow-up data on Carpentier-Edwards standard porcine
(CE-S), Carpentier-Edwards bovine pericardial (CE-P) and Carpentier-Edwards supra-
annular porcine (CE-SA) bioprostheses to generate age-dependent Weibull curves to
describe SVD. These curves were used to calculate the median time to SVD at different
patient ages of implantation. We also conducted a meta-analysis of the literature (CE-S –
3,161 patients and 22,326 patient-years; CE-P – 2,685 patients and 12,250 patient-
years; CE-SA – 3,796 patients and 20,127 patient-years) to estimate the hazards of other
valve-related events. The results of the Weibull analysis and meta-analysis were used to
parameterize a micro-simulation model, which calculated the re-operation-free life
expectancy and lifetime risk of SVD in these patients.
Results: For example, for a 65-year-old male, median time to SVD was 15.3, 20.1 and
22.2 years for the CE-S, CE-P and CE-SA valves. Re-operation-free life expectancy was
9.3, 9.9 and 10.1 years and the lifetime risk of re-operation due to SVD was 31%, 17%
and 14% respectively. For a 70-year-old male, this lifetime risk of re-operation due to
SVD was 20%, 10% and 8% respectively.
Conclusions: Estimates of SVD in the second-generation pericardial and supra-annular
bioprostheses are comparable and provide an advantage over the first-generation stan-
dard valve. Both second-generation bioprostheses offer a low lifetime risk of re-operation
for elderly patients requiring aortic valve replacement. Microsimulation provides detailed
insight into the prognosis after AVR and assists in the choice of a valve for a given
patient.
1058-68 A Virtual Heart Model for Image Orientation and 
Teaching Three-Dimensional Echocardiography
Nico Bruining, Gernoth Grunst, Thomas Berlage, Bernhard Mumm, Johannes Waldinger, 
Jos R. Roelandt, Erasmus MC, Rotterdam, The Netherlands, GMD, Sankt_Augustin, 
Germany
The interest and clinical applications of three-dimensional echocardiography (3DE) is
rapidly growing. While initially used as a research tool, real-time 3DE is currently imple-
mented in state-of-the-art ultrasound consoles. However, most echocardiographers are
familiar with two-dimensional imaging and real-time 3D volume rendered images of car-
diac pathologies often pose difficulties in understanding both the origin and orientation of
the reconstructed tomographic views used for analysis. This phenomenon is referred to
as “lost in space”. We developed a virtual reality heart (VR) model and a demonstrator,
which can be linked to 3DE data sets, using three specific anatomical landmarks, provid-
ing spatial information and the geometric position of the heart within the 3DE data. The
demonstrator, which consists out of a dummy thorax, a space locator system and a data-
base that can be filled with 3DE data sets of cardiac pathologies, is used for virtual
echocardiographic patient examinations (fig.).We examined the usefulness of the VR
heart model integrated in commercially available 3D reconstruction and analytic software
(TomTec, Munich, Germany) in 61 3DE data sets obtained in 58 patients (24 transesoph-
ageal and 37 transthoracic examinations). In 70.3% of the cases the VR heart model was
linked to the 3DE data sets and successfully implemented in 3D reconstruction software
Age-sex standardized rates per 100,000 BC residents
1995 1996 1997 1998 1999 2000 2001
Acute Coronary Syndromes 477 484 434 442 440 430
Coronary Angiography 352 354 352 356 368 393 400
Percutaneous Coronary 
Intervention
101 108 113 122 131 144 154
Coronary Artery Bypass 
Grafting
73 75 76 79 77 75 70
